{"gene":"ERBB3","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":1994,"finding":"ErbB3 is a receptor for heregulin (HRG): radiolabeled HRG-beta1 EGF-like domain bound specifically to insect cell-expressed ErbB3 (Kd ~0.85 nM) and to ErbB3-transfected NIH3T3 fibroblasts (Kd ~60 pM). Chemical cross-linking demonstrated direct binding to a 170-180 kDa ErbB3 protein, and HRG stimulated tyrosine phosphorylation of both ErbB3 and co-expressed p185erbB2/neu.","method":"Radioligand binding assay, chemical cross-linking, immunoprecipitation, tyrosine phosphorylation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct binding assay with Kd quantification, cross-linking, and functional phosphorylation readout; foundational ligand identification study","pmids":["8188716"],"is_preprint":false},{"year":1994,"finding":"NDF/heregulin (NDF) stimulates tyrosine phosphorylation of HER3/ErbB3 in breast carcinoma cell lines and HER3-transfected CHO cells, and induces receptor hetero-oligomerization (>400 kDa complex detected by cross-linking and anti-HER3 immunoprecipitation), suggesting NDF is a ligand for HER3.","method":"Tyrosine phosphorylation assay, 125I-NDF cross-linking, immunoprecipitation","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — corroborates ligand identity with phosphorylation and cross-linking, but single lab with two orthogonal methods","pmids":["8045292"],"is_preprint":false},{"year":1995,"finding":"ErbB3 (and ErbB4) are localized at neuromuscular synaptic sites in adult rodent skeletal muscle, remaining concentrated there after denervation, indicating postsynaptic membrane localization independent of innervation.","method":"Immunohistochemistry with ErbB-specific antibodies in rodent skeletal muscle, denervation experiment","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization by immunohistochemistry with functional context (denervation control), single lab","pmids":["8846777"],"is_preprint":false},{"year":1996,"finding":"In cultured rat hepatocytes, heregulin-beta1 (HRGbeta1) binds specifically to ErbB3 (cross-linking confirmed), induces ErbB3 phosphorylation, and decreases ErbB3 protein levels (indicating ligand-induced receptor trafficking/downregulation). Insulin inhibits HRGbeta1 binding and reduces ErbB3 protein levels, revealing insulin-mediated regulation of ErbB3 expression.","method":"125I-HRGbeta1 binding assay, chemical cross-linking, Western blotting, DNA synthesis assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding and cross-linking with functional (phosphorylation, trafficking) readouts; single lab, multiple orthogonal methods","pmids":["8662847"],"is_preprint":false},{"year":1998,"finding":"ErbB3 interacts with the p85 regulatory subunit of PI3K via its YXXM motifs: a single YXXM motif was necessary and sufficient for ErbB3/p85 association, multiple YXXM motifs strengthened the interaction, and the p85 SH3 domain contributed to but was not required for the interaction. The proline-rich region of ErbB3 was not required.","method":"Yeast two-hybrid with chimeric ErbB3 (EGFR kinase domain fused to ErbB3 C-terminus), ErbB3 deletion and Tyr→Phe site-specific mutants, in vitro binding assay","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis (deletion and point mutants) plus in vitro binding assay defining minimal interaction domain, rigorous mechanistic dissection","pmids":["9677338"],"is_preprint":false},{"year":2003,"finding":"ErbB3 is constitutively phosphorylated and bound to PI3K in signet-ring cell (dedifferentiated) gastric carcinoma cells. Expression of a constitutively active ErbB2/ErbB3 chimeric receptor in differentiated adenocarcinoma cells induced dedifferentiated phenotypes (loss of cell-cell interaction, high MUC1/DF3 expression), demonstrating that ErbB3 phosphorylation drives dedifferentiated malignant phenotypes.","method":"Protein purification and identification by mass spectrometry, constitutively active chimeric receptor expression, phenotypic analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function chimeric receptor with defined phenotypic readout, single lab, multiple cell lines","pmids":["12618754"],"is_preprint":false},{"year":2005,"finding":"In zebrafish, erbb3 and erbb2 are required for Schwann cell migration and the onset of myelination in vivo. Genetic mutations in erbb3 disrupt Schwann cell proliferation and migration (but not survival), and pharmacological ErbB inhibition at post-migratory stages blocks proliferation and terminal differentiation of myelinating Schwann cells.","method":"Zebrafish forward genetic screen, BrdU incorporation, time-lapse imaging, pharmacological ErbB inhibition at defined developmental stages","journal":"Current biology : CB","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic loss-of-function with multiple cellular readouts (proliferation, migration, myelination), stage-specific pharmacological validation, replicated across two genes","pmids":["15797019"],"is_preprint":false},{"year":2006,"finding":"ErbB3-dependent signaling through ErbB3/ErbB2 heterodimers enhances tumor cell intravasation and lung metastasis in orthotopic breast cancer models. Increasing ErbB3 expression enhances chemotaxis and invasion responses to heregulin-beta1, while suppression of ErbB3 reduces both intravasation and metastasis with no effect on primary tumor growth or microvessel density.","method":"Orthotopic injection models, ErbB3 overexpression and siRNA knockdown, chemotaxis/invasion assays, intravasation quantification","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal gain- and loss-of-function with specific phenotypic readouts in vivo and in vitro, single lab","pmids":["16452197"],"is_preprint":false},{"year":2006,"finding":"ErbB3 undergoes nuclear localization in prostate cancer cells; nuclear ErbB3 is significantly more prevalent in hormone-refractory tissues (100%) versus hormone-sensitive tissues (40%), detected by immunohistochemistry of 143 prostate cancer samples and confirmed by subcellular fractionation Western blotting of prostate cancer cell lines.","method":"Immunohistochemistry on tissue sections and TMA, subcellular fractionation followed by Western blotting","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct fractionation confirming nuclear localization correlated with hormone-refractory status, multiple methods, single lab","pmids":["16675564"],"is_preprint":false},{"year":2007,"finding":"MET amplification drives gefitinib resistance by activating ERBB3 (HER3)-dependent PI3K signaling. MET-amplified gefitinib-resistant lung cancer cells show MET-driven HER3 phosphorylation, and combined inhibition of MET restored gefitinib sensitivity. This demonstrated that MET can activate a pathway (ErbB3→PI3K) previously thought specific to EGFR/ErbB family receptors.","method":"Cell line resistance model, combinatorial kinase inhibition, phosphorylation analysis, MET amplification detected in patient specimens","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanism defined by pharmacological rescue, orthogonal inhibition experiments, validated in patient specimens across multiple labs","pmids":["17463250"],"is_preprint":false},{"year":2007,"finding":"Loss-of-function of ERBB3 (aberrant splicing leading to truncated protein) causes lethal congenital contractural syndrome type 2 (LCCS2), an autosomal recessive neurogenic arthrogryposis with anterior horn atrophy, establishing that ERBB3 is essential in vivo for generation of Schwann cell precursors that accompany peripheral motor axons.","method":"Human genetic mapping, identification of disease-causing ERBB3 splicing mutation in affected families","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — human loss-of-function mutation with defined cellular mechanism (Schwann cell precursor generation), replicated across affected families","pmids":["17701904"],"is_preprint":false},{"year":2008,"finding":"ErbB3 and ErbB2 are required for amputation-induced proliferation and migration during zebrafish fin regeneration. NRG1 and PI3K functionally interact with ErbB2/ErbB3 in this process; genetic or chemical inhibition of ErbB signaling reduces progenitor proliferation and migration and expression of transcription factors lef1 and msxB.","method":"Zebrafish genetic and chemical modulation of ErbB2/ErbB3, BrdU labeling, cell migration assays, gene expression analysis","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — combined genetic and pharmacological epistasis in an in vivo regeneration model, single lab with multiple orthogonal approaches","pmids":["19133254"],"is_preprint":false},{"year":2009,"finding":"Necl-2 (an immunoglobulin-like cell adhesion molecule) interacts in cis with the extracellular region of ErbB3 (but not ErbB2), reducing ligand-induced ErbB2-catalyzed tyrosine phosphorylation of ErbB3. This inhibitory effect is mediated by the protein-tyrosine phosphatase PTPN13, which interacts with the cytoplasmic tail of Necl-2, resulting in inhibition of ErbB3-mediated Rac and Akt activation and suppression of cancer cell movement and survival.","method":"Co-immunoprecipitation, domain-specific interaction mapping, siRNA knockdown, Rac/Akt activity assays, cell migration and survival assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP with mechanistic dissection of inhibitory pathway, single lab, multiple orthogonal methods","pmids":["19561085"],"is_preprint":false},{"year":2010,"finding":"Despite lacking several key conserved catalytic residues including the catalytic base aspartate, ErbB3 retains sufficient kinase activity to robustly trans-autophosphorylate its intracellular region. The ErbB3 kinase domain binds ATP with Kd ~1.1 µM. Crystal structure of ErbB3 kinase bound to an ATP analogue revealed an inactive-like configuration with a shortened αC-helix. QM/MM simulations defined a phosphoryl transfer reaction pathway that does not require the conserved catalytic base.","method":"In vitro kinase assay, ATP binding assay, X-ray crystallography, quantum mechanics/molecular mechanics (QM/MM) simulation, mutagenesis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus in vitro biochemical assays plus mutagenesis plus computational mechanistic modeling, multiple orthogonal Tier 1 methods in one study","pmids":["20351256"],"is_preprint":false},{"year":2011,"finding":"Nrdp1 (RING finger E3 ubiquitin ligase) preferentially associates with the nascent form of ErbB3 at the endoplasmic reticulum (ER), mediating ligand-independent ubiquitination and degradation of ErbB3 via the ER-associated degradation (ERAD) pathway (VCP/p97-dependent). Blocking ER exit does not affect Nrdp1-mediated ubiquitination, and disruption of VCP/p97 accumulates ubiquitinated ErbB3 without degradation.","method":"Co-localization at ER, ubiquitination assays, VCP/p97 dominant-negative and siRNA, protein stability assays, fluorescence microscopy","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — defined ER co-localization, ERAD pathway requirement established by multiple mechanistic perturbations, rigorous controls","pmids":["21576364"],"is_preprint":false},{"year":2011,"finding":"Inhibition of PI3K (with XL147) in HER2-overexpressing breast cancer cells causes feedback upregulation of HER3 expression and phosphorylation via FoxO1/FoxO3a transcription factors. Knockdown of FoxO1/FoxO3a suppressed HER3 induction; co-targeting HER3 with siRNA or HER2 inhibitors enhanced PI3K inhibitor efficacy, establishing a feedback loop limiting PI3K inhibitor effectiveness.","method":"siRNA knockdown, PI3K inhibitor treatment, Western blotting for pathway activation, co-treatment experiments, xenograft models","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic (siRNA) and pharmacological dissection of feedback loop, in vitro and in vivo validation, multiple orthogonal approaches","pmids":["21368164"],"is_preprint":false},{"year":2011,"finding":"ErbB3 loss in luminal mammary epithelium of mice impairs Akt and MAPK signaling, reduces luminal cell proliferation and survival, and shifts gene expression toward a basal/stem cell signature. ErbB3 depletion-induced effects were rescued by activation of Akt and MAPK. Interestingly, luminal ErbB3 loss induced IL-6 and other cytokines that increased growth of basal epithelial cells in a paracrine fashion.","method":"Conditional knockout mice, gene expression profiling, siRNA, Akt/MAPK pathway activation rescue experiments, cytokine analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional knockout with epistatic rescue experiments and multiple cellular readouts, in vivo model","pmids":["22178756"],"is_preprint":false},{"year":2013,"finding":"Following heregulin stimulation, erbB3 immunoprecipitates show markedly upregulated kinase activity. Intact activated erbB3 can phosphorylate tyrosine sites in an exogenous peptide substrate, and this activity is abolished by mutagenesis of lysine 723 in the catalytic domain. Enhanced erbB3 kinase activity is dependent on heterointeractions with catalytically active erbB2 (blocked by lapatinib or pertuzumab). Single-particle tracking showed erbB3 homo- and heterodimerization events in real time on live cells.","method":"Kinase activity assay from immunoprecipitates, K723 mutagenesis, lapatinib/pertuzumab inhibition, single-particle quantum dot tracking on live cells","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay with mutagenesis of catalytic residue plus live-cell single-molecule imaging, multiple Tier 1 methods","pmids":["24379439"],"is_preprint":false},{"year":2013,"finding":"ERBB3 somatic mutations (~11% in colon and gastric cancers) transform colonic and breast epithelial cells in a ligand-independent manner, but oncogenic ERBB3 mutant activity is dependent on kinase-active ERBB2. Anti-ERBB antibodies and small molecule inhibitors block mutant ERBB3-mediated oncogenic signaling in vivo.","method":"Sequencing of primary tumors, cellular transformation assay, ERBB2 knockdown/inhibition epistasis, in vivo xenograft models","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional characterization of oncogenic mutations with epistasis (ERBB2 dependency), transformation assay, in vivo validation","pmids":["23680147"],"is_preprint":false},{"year":2014,"finding":"NEDD4 (E3 ubiquitin ligase) negatively regulates HER3 levels and signaling: NEDD4 WW domains interact with the C-terminal tail of HER3 in a neuregulin-1-independent manner. NEDD4 shRNA knockdown elevated HER3 levels and increased HER3 signaling and cancer cell proliferation in vitro and in vivo.","method":"Co-immunoprecipitation, domain mapping, shRNA knockdown, proliferation assays, xenograft models, prostate cancer tissue analysis","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP with domain mapping, gain-of-function (KD of ligase elevates substrate), in vitro and in vivo validation","pmids":["24662824"],"is_preprint":false},{"year":2014,"finding":"TX1-85-1, a covalent ligand, forms a bond with Cys721 in the ATP-binding site of HER3 and inhibits HER3 signaling. Derivatization with hydrophobic adamantane (TX2-121-1) enhances inhibition, causes partial HER3 degradation, and interferes with productive heterodimerization of HER3 with HER2 or c-Met, demonstrating that covalent modification of HER3's pseudokinase ATP site is pharmacologically tractable.","method":"Covalent ligand synthesis, mass spectrometry confirmation of covalent modification, cell signaling Western blots, co-immunoprecipitation of HER3 heterodimers","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — covalent modification confirmed by MS with functional signaling and dimerization readouts; first demonstration of HER3 ATP-site druggability","pmids":["25326665"],"is_preprint":false},{"year":2017,"finding":"EGF and NRG induce HER3 phosphorylation via distinct oligomeric mechanisms depending on co-receptor context. NRG-induced HER3 phosphorylation by EGFR requires asymmetric kinase dimerization without higher-order oligomers; EGF-induced HER3 phosphorylation occurs via a noncanonical mechanism within large receptor clusters; NRG-induced HER3 phosphorylation by HER2 requires cluster formation and asymmetric kinase dimerization.","method":"STORM super-resolution microscopy with pair-correlation analysis, receptor phosphorylation assays, ligand-specific stimulation conditions","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — super-resolution microscopy combined with phosphorylation assays defining distinct mechanisms for each ligand/co-receptor context, multiple orthogonal approaches","pmids":["28320942"],"is_preprint":false},{"year":2017,"finding":"ROR1 phosphorylates HER3 at Tyr1307 (a previously unidentified site) following neuregulin stimulation, independently of other ErbB family members. Phospho-HER3 Tyr1307 recruits the LLGL2-MAYA-NSUN6 RNA-protein complex, which methylates MST1 (Hippo kinase) at Lys59, leading to MST1 inactivation and YAP target gene activation, osteoclast differentiation, and bone metastasis.","method":"Co-immunoprecipitation, phosphospecific antibodies, mutagenesis, RNA-protein complex isolation, methylation assay, in vivo bone metastasis models","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — novel phosphorylation site identified with functional downstream cascade dissected through multiple Co-IPs, mutagenesis, and in vivo validation","pmids":["28114269"],"is_preprint":false},{"year":2018,"finding":"Lapatinib (ATP-competitive HER2 inhibitor) stabilizes a specific HER2 conformer that drives HER2-HER3 kinase domain heterocomplex formation in a head-to-head orientation distinct from the canonical asymmetric active dimer. This atypical dimer, combined with HER3 ligand NRG, cooperatively promotes proliferation, providing a mechanistic basis for inhibitor-induced paradoxical pro-proliferative signaling.","method":"FRET-based conformational assay, Co-IP of kinase domain complexes, structural modeling, proliferation assays with lapatinib + NRG combinations","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — conformational and biochemical evidence for novel dimer interface combined with functional (proliferation) consequence, multiple complementary methods","pmids":["29712619"],"is_preprint":false},{"year":2018,"finding":"In untransformed cells, HER3 is not phosphorylated by MET in response to ligand stimulation but rather by ligand-independent MET activation caused by MET overexpression. MET phosphorylates HER3 via a mechanism not requiring the allosteric site used by canonical co-receptors EGFR/HER2. HER3 preferentially interacts with MET during maturation along the secretory pathway (before MET extracellular domain cleavage), resulting in accumulation of phospho-HER3 in the Golgi.","method":"Co-immunoprecipitation at different maturation states, phosphorylation assays with MET overexpression, allosteric site mutagenesis, subcellular fractionation","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — mechanistic dissection of a non-canonical phosphorylation mechanism with Golgi localization, mutagenesis of interaction site, multiple orthogonal approaches","pmids":["30390071"],"is_preprint":false},{"year":2020,"finding":"Single-molecule analysis of endogenous HER2-HER3 heterodimers revealed large conformational fluctuations in juxtamembrane and kinase domains. Despite these fluctuations, individual HER2-HER3 heterodimers catalyze tyrosine phosphorylation at an unusually high rate while simultaneously interacting with multiple downstream signaling effectors, explaining the exceptional signaling potency of this heterodimer.","method":"Single-molecule immunoprecipitation, single-molecule FRET, single-molecule kinase activity assay with endogenous receptors","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1 / Strong — single-molecule biochemical reconstitution with endogenous receptors, measuring both conformational dynamics and catalytic rate directly","pmids":["32267234"],"is_preprint":false},{"year":2021,"finding":"Cryo-EM structure of the NRG1β-bound near full-length HER2-HER3 dimer revealed that the HER3 dimerization arm is unresolved because apo HER2 does not undergo the ligand-induced conformational change needed to form a HER3 dimerization arm-binding pocket. The oncogenic HER2(S310F) mutant compensates via a stabilizing interaction with the HER3 dimerization arm. Trastuzumab binds both complexes but pertuzumab does not bind HER2(S310F)-HER3, and the HER2(S310F)-HER3 complex undergoes conformational change to accommodate trastuzumab.","method":"Cryo-electron microscopy of near full-length HER2-HER3 and HER2(S310F)-HER3 complexes, Fab binding studies","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — cryo-EM structure with functional validation of antibody binding, multiple structures including mutant and antibody-bound states","pmids":["34759323"],"is_preprint":false},{"year":2021,"finding":"Co-occurring HER3(E928G) kinase domain mutation enhances HER2/HER3 heterodimerization affinity and reduces neratinib binding to HER2. Co-expression of mutant HER2/HER3 enhances HER2/HER3 co-immunoprecipitation and ligand-independent activation of HER2/HER3 and PI3K/AKT, promoting growth, invasiveness, and resistance to HER2-targeted therapies reversible by PI3Kα inhibitors.","method":"Computational structural modeling, co-immunoprecipitation, phosphorylation assays, cell proliferation/invasion assays, PI3Kα inhibitor rescue","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — integrated computational and biochemical/cell biological dissection with epistatic rescue, multiple orthogonal methods","pmids":["34171264"],"is_preprint":false},{"year":2021,"finding":"SorLA interacts directly with HER3, forming a trimeric complex with HER2 and HER3 that attenuates lysosomal degradation of the HER2-HER3 dimer in a Rab4-dependent manner. HRG-mediated signaling supports SorLA transcription downstream of MAPK, creating a feed-forward loop. Loss of SorLA compromised heregulin-induced proliferation and sensitized resistant breast cancer cells to neratinib.","method":"Co-immunoprecipitation, Rab4 dominant-negative experiments, lysosomal degradation assays, MAPK inhibition, in vivo zebrafish xenograft model","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP and mechanistic dissection of receptor stabilization pathway with in vivo validation, single lab","pmids":["33420373"],"is_preprint":false},{"year":2013,"finding":"MTK1 (MAP3K4/MEKK4) associates with activated HER3 following HRG-beta1 stimulation in an HER2-activation-dependent manner (blocked by lapatinib). MTK1 is required for HER2/HER3-HRG-induced cell migration and extracellular acidification in breast cancer cells; disruption of actin polymerization inhibits HRG-induced MTK1/HER3 association.","method":"Co-immunoprecipitation, lapatinib treatment, cytochalasin D treatment, MTK1 knockdown, migration/acidification assays","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP with multiple mechanistic perturbations and defined functional readouts, single lab","pmids":["24036211"],"is_preprint":false},{"year":2016,"finding":"Hepatocyte-specific knockout of ERBB3 (alone or combined with EGFR) diminishes CCl4-induced liver fibrosis in mice, with maximal reduction in the ERBB3 and EGFR-ERBB3 double knockout models. This suggests that EGFR-ERBB3 heterodimeric signaling in hepatocytes plays a more important role in fibrogenesis than EGFR homodimeric signaling.","method":"Hepatocyte-specific conditional knockout mice (single and double), CCl4-induced fibrosis model, alpha-SMA quantification, immunohistochemistry","journal":"American journal of physiology. Gastrointestinal and liver physiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional knockout with epistatic double-KO analysis in well-established disease model with quantitative phenotypic readouts","pmids":["27586651"],"is_preprint":false},{"year":1993,"finding":"Alternative splicing of the c-erbB3 gene produces a 1.4-kb transcript encoding a secreted ErbB3 receptor isoform (erbB3-S), in addition to the full-length transmembrane receptor encoded by the 6.2-kb transcript.","method":"Northern blot, RACE cloning, cDNA sequencing, genomic structure analysis","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct sequencing and genomic structure analysis establishing splice isoform, single lab","pmids":["7685162"],"is_preprint":false},{"year":2024,"finding":"ErbB3 is upregulated in pulmonary artery endothelial cells in pulmonary hypertension. Endothelial cell-specific ErbB3 knockout reduces hypoxia-induced endothelial proliferation, pulmonary artery remodeling, and right ventricular hypertrophy in rodent PH models, while ErbB3 overexpression exacerbates PH. Co-immunoprecipitation and proteomic analysis identified YB-1 as a downstream target; ErbB3 induces nuclear translocation of YB-1, promoting HIF-1/2α transcription. A positive ErbB3-periostin-HIF-1/2α loop was identified.","method":"Endothelial cell-specific conditional knockout, AAV-mediated overexpression, co-immunoprecipitation, proteomics, nuclear translocation assays, rodent PH models","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific conditional KO plus overexpression with mechanistic downstream target identification by Co-IP/proteomics, in vivo validation","pmids":["38214194"],"is_preprint":false}],"current_model":"ERBB3/HER3 is a receptor tyrosine kinase that binds neuregulin/heregulin ligands via its extracellular domain and signals exclusively through heterodimerization with kinase-active partners (primarily HER2/ERBB2, also EGFR and HER4): although its kinase domain has minimal but non-zero catalytic activity (capable of ATP binding with Kd ~1 µM and trans-autophosphorylation via a non-canonical mechanism lacking the conserved catalytic base), productive phosphorylation of HER3's six YXXM motifs requires transphosphorylation by partner kinases, which then enables direct high-affinity recruitment of the PI3K p85 subunit and potent PI3K/AKT pathway activation; receptor levels are regulated by NEDD4 and Nrdp1 E3 ubiquitin ligases at the endoplasmic reticulum (ERAD pathway), with MET overexpression additionally phosphorylating HER3 in the Golgi during receptor maturation; HER3 is essential in vivo for Schwann cell migration and myelination, mammary epithelial homeostasis, and liver fibrogenesis, and its dysregulation — through overexpression, oncogenic somatic mutations, or feedback upregulation — drives resistance to EGFR/HER2-targeted therapies primarily via sustained PI3K/AKT signaling."},"narrative":{"mechanistic_narrative":"ERBB3/HER3 is a neuregulin/heregulin receptor that operates as a signal-amplifying heterodimerization partner rather than an autonomous kinase, coupling ligand binding to potent PI3K/AKT activation across development, tissue homeostasis, and cancer [PMID:8188716, PMID:9677338]. Its extracellular domain binds heregulin with high affinity, triggering tyrosine phosphorylation of HER3 and receptor hetero-oligomerization [PMID:8188716, PMID:8045292]. Although its kinase domain lacks several conserved catalytic residues including the catalytic base aspartate, it binds ATP (Kd ~1.1 µM) and supports trans-autophosphorylation through a non-canonical phosphoryl transfer pathway, adopting an inactive-like configuration [PMID:20351256]; productive phosphorylation, however, depends on catalytically active partner kinases — heregulin-stimulated HER3 kinase activity and signaling require heterointeraction with ERBB2 and are abolished by lapatinib or pertuzumab [PMID:24379439]. Phosphorylated HER3 presents YXXM motifs that directly recruit the PI3K p85 subunit, with a single motif sufficient and multiple motifs strengthening the interaction, providing the molecular basis for its exceptional PI3K coupling [PMID:9677338]. The HER2-HER3 heterodimer is an unusually potent signaling unit that catalyzes tyrosine phosphorylation at high rates while engaging multiple effectors simultaneously [PMID:32267234, PMID:34759323]. Receptor abundance is restrained by the E3 ubiquitin ligases Nrdp1, which targets nascent HER3 for ERAD at the ER, and NEDD4, which binds the HER3 C-terminal tail [PMID:21576364, PMID:24662824]. In vivo, ERBB3 is required for Schwann cell precursor generation, migration, and myelination, and human loss-of-function splicing mutations cause lethal congenital contractural syndrome type 2 (LCCS2) [PMID:15797019, PMID:17701904]; it also drives mammary luminal epithelial homeostasis and hepatocyte fibrogenesis [PMID:22178756, PMID:27586651]. HER3 dysregulation — via overexpression, oncogenic somatic mutations dependent on kinase-active ERBB2, MET-driven phosphorylation, or FoxO-mediated feedback upregulation after PI3K inhibition — sustains PI3K/AKT signaling and underlies resistance to EGFR/HER2-targeted therapy [PMID:17463250, PMID:21368164, PMID:23680147, PMID:34171264], and its ATP-binding site is covalently druggable despite minimal catalytic function [PMID:25326665].","teleology":[{"year":1994,"claim":"Establishing that ErbB3 is a direct heregulin/NDF receptor answered what ligand engages this orphan ErbB member and showed ligand binding couples to tyrosine phosphorylation of both ErbB3 and a partner receptor.","evidence":"Radioligand binding, chemical cross-linking, and phosphorylation assays in transfected cells and breast carcinoma lines","pmids":["8188716","8045292"],"confidence":"High","gaps":["Did not establish whether ErbB3 signals autonomously or requires a heterodimeric partner","Identity of the >400 kDa hetero-oligomer partner not molecularly defined at this stage"]},{"year":1995,"claim":"Synaptic localization of ErbB3 at neuromuscular junctions independent of innervation pointed to a tissue role beyond mitogenic signaling.","evidence":"Immunohistochemistry with denervation controls in rodent skeletal muscle","pmids":["8846777"],"confidence":"Medium","gaps":["No causal functional consequence demonstrated","Downstream signaling at synapse not addressed"]},{"year":1998,"claim":"Mapping the YXXM motifs as the p85/PI3K docking sites defined the molecular basis for HER3's strong coupling to PI3K/AKT.","evidence":"Yeast two-hybrid with chimeric receptor, deletion and Tyr→Phe mutants, in vitro binding","pmids":["9677338"],"confidence":"High","gaps":["Used a chimeric receptor with EGFR kinase domain, leaving native phosphorylation source unaddressed","Stoichiometry and signaling output of multi-motif binding not quantified"]},{"year":2003,"claim":"Constitutive ErbB3 phosphorylation/PI3K binding driving dedifferentiated phenotypes linked HER3 signaling to malignant cell-state change.","evidence":"Mass spectrometry identification and constitutively active ErbB2/ErbB3 chimera in gastric carcinoma cells","pmids":["12618754"],"confidence":"Medium","gaps":["Chimeric construct not equivalent to endogenous receptor regulation","Causality between PI3K and dedifferentiation not isolated"]},{"year":2005,"claim":"In vivo genetics established ERBB3 as essential for Schwann cell proliferation, migration, and myelination, defining its developmental role.","evidence":"Zebrafish forward genetics, BrdU, time-lapse imaging, stage-specific ErbB inhibition","pmids":["15797019"],"confidence":"High","gaps":["Did not separate ErbB3-intrinsic versus ErbB2-dependent contributions to each phenotype","Downstream effector pathway in Schwann cells not defined"]},{"year":2006,"claim":"Reciprocal manipulation showed ErbB3/ErbB2 signaling drives breast tumor intravasation and metastasis without affecting primary growth, separating its invasive role from proliferation.","evidence":"Orthotopic models with overexpression and siRNA, chemotaxis/invasion and intravasation assays","pmids":["16452197"],"confidence":"Medium","gaps":["Effector pathway linking HER3 to invasion not identified","Single lab"]},{"year":2006,"claim":"Nuclear ErbB3 enriched in hormone-refractory prostate cancer raised a non-canonical subcellular role correlated with disease progression.","evidence":"IHC of 143 samples and subcellular fractionation Western blotting","pmids":["16675564"],"confidence":"Medium","gaps":["Mechanism of nuclear translocation unknown","Functional role of nuclear HER3 not established"]},{"year":2007,"claim":"MET amplification activating ERBB3-dependent PI3K signaling answered how cancers bypass EGFR inhibition, expanding HER3's partner repertoire beyond ErbB receptors.","evidence":"MET-amplified resistant lung cancer lines, combinatorial kinase inhibition, patient specimen analysis","pmids":["17463250"],"confidence":"High","gaps":["Direct versus indirect MET-HER3 phosphorylation not resolved at this stage","Subcellular site of MET-HER3 interaction undefined"]},{"year":2007,"claim":"A human loss-of-function ERBB3 splicing mutation causing LCCS2 confirmed in vivo essentiality for Schwann cell precursor generation and motor axon accompaniment.","evidence":"Genetic mapping and disease-causing mutation identification in affected families","pmids":["17701904"],"confidence":"High","gaps":["Cellular mechanism of precursor failure not dissected biochemically","No genotype-phenotype correlation beyond truncating allele"]},{"year":2009,"claim":"Necl-2/PTPN13-mediated cis inhibition of ErbB2-catalyzed ErbB3 phosphorylation identified a negative regulatory axis controlling HER3 output.","evidence":"Co-IP, domain mapping, siRNA, Rac/Akt activity and migration/survival assays","pmids":["19561085"],"confidence":"Medium","gaps":["Physiological contexts where Necl-2 regulates HER3 not defined","Single lab"]},{"year":2010,"claim":"Structural and biochemical analysis showed the HER3 'pseudokinase' binds ATP and trans-autophosphorylates via a base-independent mechanism, redefining it as a weakly active rather than dead kinase.","evidence":"In vitro kinase and ATP-binding assays, X-ray crystallography, QM/MM simulation, mutagenesis","pmids":["20351256"],"confidence":"High","gaps":["Physiological significance of low intrinsic activity versus partner-driven phosphorylation unresolved","In vivo contribution of autophosphorylation not tested"]},{"year":2011,"claim":"Nrdp1 and FoxO-driven feedback findings defined opposing controls on HER3 abundance — ERAD degradation of nascent receptor and transcriptional induction upon PI3K inhibition that limits drug efficacy.","evidence":"ER co-localization and ubiquitination/VCP perturbation assays; PI3K inhibitor treatment with FoxO1/3a knockdown and xenografts","pmids":["21576364","21368164"],"confidence":"High","gaps":["Interplay between ERAD turnover and feedback transcription not integrated","Trigger selecting nascent versus mature HER3 for Nrdp1 incompletely defined"]},{"year":2011,"claim":"Conditional knockout showed luminal mammary ErbB3 sustains Akt/MAPK-dependent proliferation and survival and represses a basal/stem program, with paracrine cytokine consequences.","evidence":"Conditional knockout mice, expression profiling, Akt/MAPK rescue, cytokine analysis","pmids":["22178756"],"confidence":"High","gaps":["Direct transcriptional targets of HER3 signaling in luminal cells not mapped","Paracrine IL-6 source and receptor circuit only partially defined"]},{"year":2013,"claim":"Heregulin-induced HER3 kinase activity dependent on K723 and on catalytically active ERBB2, plus live-cell dimerization imaging, reconciled intrinsic activity with obligate partner dependence.","evidence":"Kinase assay from immunoprecipitates, K723 mutagenesis, lapatinib/pertuzumab inhibition, single-particle tracking","pmids":["24379439"],"confidence":"High","gaps":["Relative contribution of HER3 versus HER2 catalysis to substrate phosphorylation not quantified","Substrate repertoire of activated HER3 not broadly defined"]},{"year":2013,"claim":"Oncogenic ERBB3 somatic mutations transforming epithelial cells in a ligand-independent but ERBB2-dependent manner established HER3 as a cancer driver and therapeutic target.","evidence":"Tumor sequencing, transformation assays, ERBB2 epistasis, xenografts, antibody/inhibitor blockade","pmids":["23680147"],"confidence":"High","gaps":["Structural mechanism by which mutations activate signaling not resolved here","Tissue-specificity of mutation effects not addressed"]},{"year":2013,"claim":"MTK1 association with HER3 in an actin- and ERBB2-activation-dependent manner identified a migration effector downstream of HER2/HER3.","evidence":"Co-IP, lapatinib and cytochalasin D treatment, MTK1 knockdown, migration/acidification assays","pmids":["24036211"],"confidence":"Medium","gaps":["Direct versus indirect MTK1-HER3 binding not resolved","Single lab"]},{"year":2014,"claim":"NEDD4 binding the HER3 C-terminal tail and a covalent ATP-site ligand together established a second degradative regulator and the surprising druggability of the HER3 pseudokinase pocket.","evidence":"Co-IP/domain mapping with shRNA and xenografts; covalent ligand synthesis with MS confirmation and dimerization assays","pmids":["24662824","25326665"],"confidence":"High","gaps":["NEDD4 versus Nrdp1 division of labor in HER3 turnover not delineated","Cellular potency and selectivity of covalent ATP-site ligands not fully characterized"]},{"year":2017,"claim":"Super-resolution and novel-site studies revealed ligand/co-receptor-specific oligomeric mechanisms of HER3 phosphorylation and a ROR1-driven Tyr1307 branch coupling HER3 to a methylation cascade and bone metastasis.","evidence":"STORM with pair-correlation; ROR1 Co-IP, phosphospecific antibodies, methylation assays, in vivo metastasis models","pmids":["28320942","28114269"],"confidence":"High","gaps":["Generality of ROR1-Tyr1307 axis across tissues unknown","How oligomeric state selects downstream effector outputs not resolved"]},{"year":2018,"claim":"Single-molecule and mechanistic work showed HER2-HER3 dimers catalyze phosphorylation at high rates despite conformational flexibility, and that MET phosphorylates HER3 ligand-independently in the Golgi via a non-allosteric mechanism.","evidence":"Single-molecule IP/FRET/kinase assays with endogenous receptors; MET overexpression, allosteric-site mutagenesis, fractionation","pmids":["32267234","30390071"],"confidence":"High","gaps":["In vivo relevance of Golgi-localized phospho-HER3 not established","How the secretory-pathway HER3-MET interaction influences surface signaling unclear"]},{"year":2021,"claim":"Cryo-EM, mutation, and trafficking studies defined the structural basis of HER2-HER3 dimerization, how oncogenic mutations (HER2 S310F, HER3 E928G) reshape the dimer and drug binding, and how SorLA stabilizes the dimer against lysosomal degradation.","evidence":"Cryo-EM with Fab binding; structural modeling, Co-IP, proliferation/invasion and PI3Kα rescue; SorLA Co-IP, Rab4 perturbation, zebrafish xenografts","pmids":["34759323","34171264","33420373"],"confidence":"High","gaps":["Structure of the HER3 kinase-active or fully signaling-competent dimer not captured","SorLA findings are single-lab and lack reciprocal structural validation"]},{"year":2024,"claim":"Endothelial ERBB3 was shown to drive pulmonary hypertension through a YB-1/HIF and periostin feed-forward loop, extending HER3 biology to vascular remodeling.","evidence":"Endothelial-specific knockout and AAV overexpression in rodent PH, Co-IP/proteomics, nuclear translocation assays","pmids":["38214194"],"confidence":"High","gaps":["Whether the YB-1 axis requires canonical HER3 PI3K signaling not dissected","Ligand/partner driving endothelial HER3 activation in PH undefined"]},{"year":null,"claim":"How HER3's distinct activation routes (partner ErbB kinases, MET, ROR1) and degradation controls (Nrdp1, NEDD4) are integrated to set context-specific signaling output and effector selection remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking oligomeric state, phospho-site usage, and downstream effector choice","Functional role of nuclear and secreted HER3 isoforms not established","In vivo contribution of intrinsic HER3 catalysis versus partner phosphorylation untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[13,17]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[13]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[0]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[4]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,2,17]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[14]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[24]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[8]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,9,17]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[10,18,27]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[6,10,11]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[14,19]}],"complexes":["HER2-HER3 heterodimer","HER3-PI3K (p85) complex"],"partners":["ERBB2","EGFR","PIK3R1","MET","NEDD4","ROR1","SORL1","MAP3K4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P21860","full_name":"Receptor tyrosine-protein kinase erbB-3","aliases":["Proto-oncogene-like protein c-ErbB-3","Tyrosine kinase-type cell surface receptor HER3"],"length_aa":1342,"mass_kda":148.1,"function":"Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins. Binds to neuregulin-1 (NRG1) and is activated by it; ligand-binding increases phosphorylation on tyrosine residues and promotes its association with the p85 subunit of phosphatidylinositol 3-kinase (PubMed:20682778). May also be activated by CSPG5 (PubMed:15358134). Involved in the regulation of myeloid cell differentiation (PubMed:27416908)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P21860/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ERBB3","classification":"Not Classified","n_dependent_lines":110,"n_total_lines":1208,"dependency_fraction":0.09105960264900662},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ERBB3","total_profiled":1310},"omim":[{"mim_id":"620051","title":"RING FINGER PROTEIN 41, E3 UBIQUITIN PROTEIN LIGASE; RNF41","url":"https://www.omim.org/entry/620051"},{"mim_id":"618717","title":"EPITHELIAL MITOGEN; EPGN","url":"https://www.omim.org/entry/618717"},{"mim_id":"617090","title":"MICROCEPHALY 17, PRIMARY, AUTOSOMAL RECESSIVE; MCPH17","url":"https://www.omim.org/entry/617090"},{"mim_id":"616016","title":"PROTEIN PHOSPHATASE, MAGNESIUM/MANGANESE-DEPENDENT, 1H; PPM1H","url":"https://www.omim.org/entry/616016"},{"mim_id":"613746","title":"BREAST CANCER ANTIESTROGEN RESISTANCE 4; BCAR4","url":"https://www.omim.org/entry/613746"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Actin filaments","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ERBB3"},"hgnc":{"alias_symbol":["HER3"],"prev_symbol":["LCCS2"]},"alphafold":{"accession":"P21860","domains":[{"cath_id":"3.80.20.20","chopping":"24-206","consensus_level":"medium","plddt":91.5037,"start":24,"end":206},{"cath_id":"2.10.220.10","chopping":"264-323","consensus_level":"high","plddt":86.9925,"start":264,"end":323},{"cath_id":"3.80.20.20","chopping":"331-499","consensus_level":"medium","plddt":93.8141,"start":331,"end":499},{"cath_id":"3.30.200.20","chopping":"699-790","consensus_level":"medium","plddt":83.1429,"start":699,"end":790},{"cath_id":"1.10.510.10","chopping":"795-979","consensus_level":"medium","plddt":90.1741,"start":795,"end":979}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P21860","model_url":"https://alphafold.ebi.ac.uk/files/AF-P21860-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P21860-F1-predicted_aligned_error_v6.png","plddt_mean":72.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ERBB3","jax_strain_url":"https://www.jax.org/strain/search?query=ERBB3"},"sequence":{"accession":"P21860","fasta_url":"https://rest.uniprot.org/uniprotkb/P21860.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P21860/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P21860"}},"corpus_meta":[{"pmid":"17463250","id":"PMC_17463250","title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.","date":"2007","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/17463250","citation_count":3861,"is_preprint":false},{"pmid":"19536107","id":"PMC_19536107","title":"Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.","date":"2009","source":"Nature reviews. Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19536107","citation_count":952,"is_preprint":false},{"pmid":"29420467","id":"PMC_29420467","title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers.","date":"2018","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/29420467","citation_count":635,"is_preprint":false},{"pmid":"12648465","id":"PMC_12648465","title":"The deaf and the dumb: the biology of ErbB-2 and ErbB-3.","date":"2003","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/12648465","citation_count":469,"is_preprint":false},{"pmid":"20351256","id":"PMC_20351256","title":"ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20351256","citation_count":375,"is_preprint":false},{"pmid":"8188716","id":"PMC_8188716","title":"The erbB3 gene product is a receptor for heregulin.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8188716","citation_count":333,"is_preprint":false},{"pmid":"23680147","id":"PMC_23680147","title":"Oncogenic ERBB3 mutations in human cancers.","date":"2013","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/23680147","citation_count":304,"is_preprint":false},{"pmid":"21368164","id":"PMC_21368164","title":"Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21368164","citation_count":296,"is_preprint":false},{"pmid":"15797019","id":"PMC_15797019","title":"erbb3 and erbb2 are essential for schwann cell migration and myelination in zebrafish.","date":"2005","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/15797019","citation_count":276,"is_preprint":false},{"pmid":"28114269","id":"PMC_28114269","title":"A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis.","date":"2017","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/28114269","citation_count":268,"is_preprint":false},{"pmid":"1333787","id":"PMC_1333787","title":"Expression of the ERBB3 gene product in breast cancer.","date":"1992","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/1333787","citation_count":229,"is_preprint":false},{"pmid":"23221996","id":"PMC_23221996","title":"HER3 overexpression and survival in solid tumors: a meta-analysis.","date":"2012","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/23221996","citation_count":197,"is_preprint":false},{"pmid":"18404164","id":"PMC_18404164","title":"The ERBB3 receptor in cancer and cancer gene therapy.","date":"2008","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/18404164","citation_count":193,"is_preprint":false},{"pmid":"8846777","id":"PMC_8846777","title":"Neuregulin receptors, erbB3 and erbB4, are localized at neuromuscular synapses.","date":"1995","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8846777","citation_count":161,"is_preprint":false},{"pmid":"24520092","id":"PMC_24520092","title":"Molecular pathways: HER3 targeted therapy.","date":"2014","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/24520092","citation_count":160,"is_preprint":false},{"pmid":"30057690","id":"PMC_30057690","title":"HER3 signaling and targeted therapy in cancer.","date":"2018","source":"Oncology reviews","url":"https://pubmed.ncbi.nlm.nih.gov/30057690","citation_count":158,"is_preprint":false},{"pmid":"9823984","id":"PMC_9823984","title":"Expression of c-erbB3 protein in primary breast carcinomas.","date":"1998","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9823984","citation_count":157,"is_preprint":false},{"pmid":"25326665","id":"PMC_25326665","title":"Pharmacological targeting of the pseudokinase Her3.","date":"2014","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/25326665","citation_count":156,"is_preprint":false},{"pmid":"24886126","id":"PMC_24886126","title":"Targeting of erbB3 receptor to overcome resistance in cancer treatment.","date":"2014","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24886126","citation_count":155,"is_preprint":false},{"pmid":"18454306","id":"PMC_18454306","title":"ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.","date":"2008","source":"Journal of mammary gland biology and neoplasia","url":"https://pubmed.ncbi.nlm.nih.gov/18454306","citation_count":121,"is_preprint":false},{"pmid":"9677338","id":"PMC_9677338","title":"ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase.","date":"1998","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/9677338","citation_count":119,"is_preprint":false},{"pmid":"30109175","id":"PMC_30109175","title":"Understanding the biology of HER3 receptor as a therapeutic target in human cancer.","date":"2018","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/30109175","citation_count":108,"is_preprint":false},{"pmid":"16675564","id":"PMC_16675564","title":"Expression and nuclear localization of ErbB3 in prostate cancer.","date":"2006","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/16675564","citation_count":107,"is_preprint":false},{"pmid":"34759323","id":"PMC_34759323","title":"Structures of the HER2-HER3-NRG1β complex reveal a dynamic dimer interface.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34759323","citation_count":98,"is_preprint":false},{"pmid":"31519989","id":"PMC_31519989","title":"ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics.","date":"2019","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/31519989","citation_count":89,"is_preprint":false},{"pmid":"25400118","id":"PMC_25400118","title":"Regulation of ERBB3/HER3 signaling in cancer.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25400118","citation_count":86,"is_preprint":false},{"pmid":"16452197","id":"PMC_16452197","title":"ErbB3-dependent motility and intravasation in breast cancer metastasis.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16452197","citation_count":83,"is_preprint":false},{"pmid":"34171264","id":"PMC_34171264","title":"Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity.","date":"2021","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/34171264","citation_count":81,"is_preprint":false},{"pmid":"24379439","id":"PMC_24379439","title":"erbB3 is an active tyrosine kinase capable of homo- and heterointeractions.","date":"2013","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/24379439","citation_count":80,"is_preprint":false},{"pmid":"36271429","id":"PMC_36271429","title":"HER3 in cancer: from the bench to the bedside.","date":"2022","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/36271429","citation_count":79,"is_preprint":false},{"pmid":"17671674","id":"PMC_17671674","title":"EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases.","date":"2007","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17671674","citation_count":78,"is_preprint":false},{"pmid":"28320942","id":"PMC_28320942","title":"EGF and NRG induce phosphorylation of HER3/ERBB3 by EGFR using distinct oligomeric mechanisms.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28320942","citation_count":75,"is_preprint":false},{"pmid":"17457047","id":"PMC_17457047","title":"ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.","date":"2007","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/17457047","citation_count":75,"is_preprint":false},{"pmid":"16254079","id":"PMC_16254079","title":"The ErbB3 binding protein Ebp1 interacts with Sin3A to repress E2F1 and AR-mediated transcription.","date":"2005","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/16254079","citation_count":74,"is_preprint":false},{"pmid":"8045292","id":"PMC_8045292","title":"NDF/heregulin stimulates the phosphorylation of Her3/erbB3.","date":"1994","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/8045292","citation_count":70,"is_preprint":false},{"pmid":"34548332","id":"PMC_34548332","title":"EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd.","date":"2021","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/34548332","citation_count":69,"is_preprint":false},{"pmid":"22889873","id":"PMC_22889873","title":"The promise of anti-ErbB3 monoclonals as new cancer therapeutics.","date":"2012","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/22889873","citation_count":67,"is_preprint":false},{"pmid":"19481955","id":"PMC_19481955","title":"The upgraded role of HER3 and HER4 receptors in breast cancer.","date":"2009","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/19481955","citation_count":65,"is_preprint":false},{"pmid":"26477646","id":"PMC_26477646","title":"Affibody-mediated PET imaging of HER3 expression in malignant tumours.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26477646","citation_count":64,"is_preprint":false},{"pmid":"26496898","id":"PMC_26496898","title":"HER3/ErbB3, an emerging cancer therapeutic target.","date":"2015","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/26496898","citation_count":63,"is_preprint":false},{"pmid":"34753775","id":"PMC_34753775","title":"HER3 Is an Actionable Target in Advanced Prostate Cancer.","date":"2021","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/34753775","citation_count":63,"is_preprint":false},{"pmid":"29718453","id":"PMC_29718453","title":"Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer.","date":"2018","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/29718453","citation_count":63,"is_preprint":false},{"pmid":"24662824","id":"PMC_24662824","title":"The E3 ubiquitin ligase NEDD4 negatively regulates HER3/ErbB3 level and signaling.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24662824","citation_count":63,"is_preprint":false},{"pmid":"7685162","id":"PMC_7685162","title":"c-erbB3 gene encodes secreted as well as transmembrane receptor tyrosine kinase.","date":"1993","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/7685162","citation_count":62,"is_preprint":false},{"pmid":"22178756","id":"PMC_22178756","title":"The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22178756","citation_count":60,"is_preprint":false},{"pmid":"36764093","id":"PMC_36764093","title":"Targeting HER3 for cancer treatment: a new horizon for an old target.","date":"2023","source":"ESMO open","url":"https://pubmed.ncbi.nlm.nih.gov/36764093","citation_count":59,"is_preprint":false},{"pmid":"29712619","id":"PMC_29712619","title":"Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface.","date":"2018","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/29712619","citation_count":58,"is_preprint":false},{"pmid":"31351986","id":"PMC_31351986","title":"Mechanisms of Receptor Tyrosine-Protein Kinase ErbB-3 (ERBB3) Action in Human Neoplasia.","date":"2019","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31351986","citation_count":54,"is_preprint":false},{"pmid":"24513440","id":"PMC_24513440","title":"HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting.","date":"2014","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/24513440","citation_count":54,"is_preprint":false},{"pmid":"30930695","id":"PMC_30930695","title":"Development of Effective Therapeutics Targeting HER3 for Cancer Treatment.","date":"2019","source":"Biological procedures online","url":"https://pubmed.ncbi.nlm.nih.gov/30930695","citation_count":54,"is_preprint":false},{"pmid":"19133254","id":"PMC_19133254","title":"ErbB2 and ErbB3 regulate amputation-induced proliferation and migration during vertebrate regeneration.","date":"2008","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/19133254","citation_count":54,"is_preprint":false},{"pmid":"18852121","id":"PMC_18852121","title":"EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance.","date":"2008","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/18852121","citation_count":54,"is_preprint":false},{"pmid":"24275324","id":"PMC_24275324","title":"ErbB3 binding protein-1 (Ebp1) controls proliferation and myogenic differentiation of muscle stem cells.","date":"2013","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/24275324","citation_count":53,"is_preprint":false},{"pmid":"20647770","id":"PMC_20647770","title":"ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma.","date":"2010","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/20647770","citation_count":53,"is_preprint":false},{"pmid":"17701904","id":"PMC_17701904","title":"Lethal congenital contractural syndrome type 2 (LCCS2) is caused by a mutation in ERBB3 (Her3), a modulator of the phosphatidylinositol-3-kinase/Akt pathway.","date":"2007","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17701904","citation_count":51,"is_preprint":false},{"pmid":"29179520","id":"PMC_29179520","title":"A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29179520","citation_count":51,"is_preprint":false},{"pmid":"19561085","id":"PMC_19561085","title":"Silencing of ErbB3/ErbB2 signaling by immunoglobulin-like Necl-2.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19561085","citation_count":50,"is_preprint":false},{"pmid":"21576364","id":"PMC_21576364","title":"Quantity control of the ErbB3 receptor tyrosine kinase at the endoplasmic reticulum.","date":"2011","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/21576364","citation_count":47,"is_preprint":false},{"pmid":"24901400","id":"PMC_24901400","title":"High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.","date":"2014","source":"International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists","url":"https://pubmed.ncbi.nlm.nih.gov/24901400","citation_count":45,"is_preprint":false},{"pmid":"29944978","id":"PMC_29944978","title":"Clinical development of HER3-targeting monoclonal antibodies: Perils and progress.","date":"2018","source":"Cancer treatment reviews","url":"https://pubmed.ncbi.nlm.nih.gov/29944978","citation_count":43,"is_preprint":false},{"pmid":"25035390","id":"PMC_25035390","title":"Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25035390","citation_count":43,"is_preprint":false},{"pmid":"33907275","id":"PMC_33907275","title":"The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33907275","citation_count":42,"is_preprint":false},{"pmid":"16061682","id":"PMC_16061682","title":"ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition.","date":"2005","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16061682","citation_count":42,"is_preprint":false},{"pmid":"26529100","id":"PMC_26529100","title":"Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.","date":"2015","source":"Human vaccines & immunotherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/26529100","citation_count":41,"is_preprint":false},{"pmid":"27532938","id":"PMC_27532938","title":"Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.","date":"2016","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/27532938","citation_count":40,"is_preprint":false},{"pmid":"24449784","id":"PMC_24449784","title":"Role of erbB3 receptors in cancer therapeutic resistance.","date":"2014","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/24449784","citation_count":40,"is_preprint":false},{"pmid":"12618754","id":"PMC_12618754","title":"Activation of ErbB3-PI3-kinase pathway is correlated with malignant phenotypes of adenocarcinomas.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12618754","citation_count":39,"is_preprint":false},{"pmid":"22768204","id":"PMC_22768204","title":"Cellular effects of HER3-specific affibody molecules.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22768204","citation_count":38,"is_preprint":false},{"pmid":"38214194","id":"PMC_38214194","title":"ErbB3 Governs Endothelial Dysfunction in Hypoxia-Induced Pulmonary Hypertension.","date":"2024","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/38214194","citation_count":37,"is_preprint":false},{"pmid":"8662847","id":"PMC_8662847","title":"Insulin regulates heregulin binding and ErbB3 expression in rat hepatocytes.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8662847","citation_count":37,"is_preprint":false},{"pmid":"25849870","id":"PMC_25849870","title":"Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth.","date":"2015","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/25849870","citation_count":37,"is_preprint":false},{"pmid":"27086600","id":"PMC_27086600","title":"HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy.","date":"2016","source":"Recent patents on anti-cancer drug discovery","url":"https://pubmed.ncbi.nlm.nih.gov/27086600","citation_count":34,"is_preprint":false},{"pmid":"29325454","id":"PMC_29325454","title":"Down-expression of P2RX2, KCNQ5, ERBB3 and SOCS3 through DNA hypermethylation in elderly women with presbycusis.","date":"2018","source":"Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/29325454","citation_count":34,"is_preprint":false},{"pmid":"25046105","id":"PMC_25046105","title":"Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation.","date":"2014","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/25046105","citation_count":34,"is_preprint":false},{"pmid":"27586651","id":"PMC_27586651","title":"Hepatocyte ERBB3 and EGFR are required for maximal CCl4-induced liver fibrosis.","date":"2016","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/27586651","citation_count":32,"is_preprint":false},{"pmid":"28000159","id":"PMC_28000159","title":"HER3 as a Therapeutic Target in Cancer.","date":"2017","source":"BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/28000159","citation_count":31,"is_preprint":false},{"pmid":"39098760","id":"PMC_39098760","title":"ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/39098760","citation_count":30,"is_preprint":false},{"pmid":"16556064","id":"PMC_16556064","title":"Role of HER2/HER3 co-receptor in breast carcinogenesis.","date":"2005","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16556064","citation_count":30,"is_preprint":false},{"pmid":"23792093","id":"PMC_23792093","title":"IGF-1R and ErbB3/HER3 contribute to enhanced proliferation and carcinogenesis in trastuzumab-resistant ovarian cancer model.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23792093","citation_count":28,"is_preprint":false},{"pmid":"30390071","id":"PMC_30390071","title":"Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30390071","citation_count":28,"is_preprint":false},{"pmid":"37036472","id":"PMC_37036472","title":"Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer.","date":"2023","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/37036472","citation_count":26,"is_preprint":false},{"pmid":"37302522","id":"PMC_37302522","title":"AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors.","date":"2023","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/37302522","citation_count":25,"is_preprint":false},{"pmid":"30076717","id":"PMC_30076717","title":"The role of ErbB3 binding protein 1 in cancer: Friend or foe?","date":"2018","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30076717","citation_count":24,"is_preprint":false},{"pmid":"28248115","id":"PMC_28248115","title":"Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells.","date":"2017","source":"Molecular pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/28248115","citation_count":24,"is_preprint":false},{"pmid":"25865227","id":"PMC_25865227","title":"Novel agents that downregulate EGFR, HER2, and HER3 in parallel.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25865227","citation_count":24,"is_preprint":false},{"pmid":"40087402","id":"PMC_40087402","title":"Emerging importance of HER3 in tumorigenesis and cancer therapy.","date":"2025","source":"Nature reviews. Clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40087402","citation_count":23,"is_preprint":false},{"pmid":"20672328","id":"PMC_20672328","title":"Expression, localization, and regulation of the neuregulin receptor ErbB3 in mouse heart.","date":"2011","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/20672328","citation_count":23,"is_preprint":false},{"pmid":"19797898","id":"PMC_19797898","title":"Heregulin-induced VEGF expression via the ErbB3 signaling pathway in colon cancer.","date":"2009","source":"Digestion","url":"https://pubmed.ncbi.nlm.nih.gov/19797898","citation_count":23,"is_preprint":false},{"pmid":"26621843","id":"PMC_26621843","title":"The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26621843","citation_count":23,"is_preprint":false},{"pmid":"38239350","id":"PMC_38239350","title":"Targeting HER3 to overcome EGFR TKI resistance in NSCLC.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38239350","citation_count":22,"is_preprint":false},{"pmid":"25194439","id":"PMC_25194439","title":"The role of HER3 in gastric cancer.","date":"2014","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/25194439","citation_count":22,"is_preprint":false},{"pmid":"28886748","id":"PMC_28886748","title":"ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactation.","date":"2017","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/28886748","citation_count":22,"is_preprint":false},{"pmid":"32267234","id":"PMC_32267234","title":"Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers.","date":"2020","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/32267234","citation_count":22,"is_preprint":false},{"pmid":"35319011","id":"PMC_35319011","title":"MiR-323a regulates ErbB3/EGFR and blocks gefitinib resistance acquisition in colorectal cancer.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35319011","citation_count":21,"is_preprint":false},{"pmid":"24036211","id":"PMC_24036211","title":"HER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4).","date":"2013","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/24036211","citation_count":21,"is_preprint":false},{"pmid":"33420373","id":"PMC_33420373","title":"A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33420373","citation_count":21,"is_preprint":false},{"pmid":"32981377","id":"PMC_32981377","title":"New insights into ErbB3 function and therapeutic targeting in cancer.","date":"2020","source":"Expert review of anticancer therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32981377","citation_count":20,"is_preprint":false},{"pmid":"17983482","id":"PMC_17983482","title":"Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?","date":"2007","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/17983482","citation_count":20,"is_preprint":false},{"pmid":"36551663","id":"PMC_36551663","title":"HER3 Alterations in Cancer and Potential Clinical Implications.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36551663","citation_count":19,"is_preprint":false},{"pmid":"27017409","id":"PMC_27017409","title":"Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance.","date":"2016","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/27017409","citation_count":19,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47636,"output_tokens":8925,"usd":0.138392,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18925,"output_tokens":6532,"usd":0.128963,"stage2_stop_reason":"end_turn"},"total_usd":0.267355,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"ErbB3 is a receptor for heregulin (HRG): radiolabeled HRG-beta1 EGF-like domain bound specifically to insect cell-expressed ErbB3 (Kd ~0.85 nM) and to ErbB3-transfected NIH3T3 fibroblasts (Kd ~60 pM). Chemical cross-linking demonstrated direct binding to a 170-180 kDa ErbB3 protein, and HRG stimulated tyrosine phosphorylation of both ErbB3 and co-expressed p185erbB2/neu.\",\n      \"method\": \"Radioligand binding assay, chemical cross-linking, immunoprecipitation, tyrosine phosphorylation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct binding assay with Kd quantification, cross-linking, and functional phosphorylation readout; foundational ligand identification study\",\n      \"pmids\": [\"8188716\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"NDF/heregulin (NDF) stimulates tyrosine phosphorylation of HER3/ErbB3 in breast carcinoma cell lines and HER3-transfected CHO cells, and induces receptor hetero-oligomerization (>400 kDa complex detected by cross-linking and anti-HER3 immunoprecipitation), suggesting NDF is a ligand for HER3.\",\n      \"method\": \"Tyrosine phosphorylation assay, 125I-NDF cross-linking, immunoprecipitation\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — corroborates ligand identity with phosphorylation and cross-linking, but single lab with two orthogonal methods\",\n      \"pmids\": [\"8045292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"ErbB3 (and ErbB4) are localized at neuromuscular synaptic sites in adult rodent skeletal muscle, remaining concentrated there after denervation, indicating postsynaptic membrane localization independent of innervation.\",\n      \"method\": \"Immunohistochemistry with ErbB-specific antibodies in rodent skeletal muscle, denervation experiment\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization by immunohistochemistry with functional context (denervation control), single lab\",\n      \"pmids\": [\"8846777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"In cultured rat hepatocytes, heregulin-beta1 (HRGbeta1) binds specifically to ErbB3 (cross-linking confirmed), induces ErbB3 phosphorylation, and decreases ErbB3 protein levels (indicating ligand-induced receptor trafficking/downregulation). Insulin inhibits HRGbeta1 binding and reduces ErbB3 protein levels, revealing insulin-mediated regulation of ErbB3 expression.\",\n      \"method\": \"125I-HRGbeta1 binding assay, chemical cross-linking, Western blotting, DNA synthesis assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding and cross-linking with functional (phosphorylation, trafficking) readouts; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"8662847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"ErbB3 interacts with the p85 regulatory subunit of PI3K via its YXXM motifs: a single YXXM motif was necessary and sufficient for ErbB3/p85 association, multiple YXXM motifs strengthened the interaction, and the p85 SH3 domain contributed to but was not required for the interaction. The proline-rich region of ErbB3 was not required.\",\n      \"method\": \"Yeast two-hybrid with chimeric ErbB3 (EGFR kinase domain fused to ErbB3 C-terminus), ErbB3 deletion and Tyr→Phe site-specific mutants, in vitro binding assay\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis (deletion and point mutants) plus in vitro binding assay defining minimal interaction domain, rigorous mechanistic dissection\",\n      \"pmids\": [\"9677338\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ErbB3 is constitutively phosphorylated and bound to PI3K in signet-ring cell (dedifferentiated) gastric carcinoma cells. Expression of a constitutively active ErbB2/ErbB3 chimeric receptor in differentiated adenocarcinoma cells induced dedifferentiated phenotypes (loss of cell-cell interaction, high MUC1/DF3 expression), demonstrating that ErbB3 phosphorylation drives dedifferentiated malignant phenotypes.\",\n      \"method\": \"Protein purification and identification by mass spectrometry, constitutively active chimeric receptor expression, phenotypic analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function chimeric receptor with defined phenotypic readout, single lab, multiple cell lines\",\n      \"pmids\": [\"12618754\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"In zebrafish, erbb3 and erbb2 are required for Schwann cell migration and the onset of myelination in vivo. Genetic mutations in erbb3 disrupt Schwann cell proliferation and migration (but not survival), and pharmacological ErbB inhibition at post-migratory stages blocks proliferation and terminal differentiation of myelinating Schwann cells.\",\n      \"method\": \"Zebrafish forward genetic screen, BrdU incorporation, time-lapse imaging, pharmacological ErbB inhibition at defined developmental stages\",\n      \"journal\": \"Current biology : CB\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic loss-of-function with multiple cellular readouts (proliferation, migration, myelination), stage-specific pharmacological validation, replicated across two genes\",\n      \"pmids\": [\"15797019\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ErbB3-dependent signaling through ErbB3/ErbB2 heterodimers enhances tumor cell intravasation and lung metastasis in orthotopic breast cancer models. Increasing ErbB3 expression enhances chemotaxis and invasion responses to heregulin-beta1, while suppression of ErbB3 reduces both intravasation and metastasis with no effect on primary tumor growth or microvessel density.\",\n      \"method\": \"Orthotopic injection models, ErbB3 overexpression and siRNA knockdown, chemotaxis/invasion assays, intravasation quantification\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal gain- and loss-of-function with specific phenotypic readouts in vivo and in vitro, single lab\",\n      \"pmids\": [\"16452197\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ErbB3 undergoes nuclear localization in prostate cancer cells; nuclear ErbB3 is significantly more prevalent in hormone-refractory tissues (100%) versus hormone-sensitive tissues (40%), detected by immunohistochemistry of 143 prostate cancer samples and confirmed by subcellular fractionation Western blotting of prostate cancer cell lines.\",\n      \"method\": \"Immunohistochemistry on tissue sections and TMA, subcellular fractionation followed by Western blotting\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct fractionation confirming nuclear localization correlated with hormone-refractory status, multiple methods, single lab\",\n      \"pmids\": [\"16675564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"MET amplification drives gefitinib resistance by activating ERBB3 (HER3)-dependent PI3K signaling. MET-amplified gefitinib-resistant lung cancer cells show MET-driven HER3 phosphorylation, and combined inhibition of MET restored gefitinib sensitivity. This demonstrated that MET can activate a pathway (ErbB3→PI3K) previously thought specific to EGFR/ErbB family receptors.\",\n      \"method\": \"Cell line resistance model, combinatorial kinase inhibition, phosphorylation analysis, MET amplification detected in patient specimens\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanism defined by pharmacological rescue, orthogonal inhibition experiments, validated in patient specimens across multiple labs\",\n      \"pmids\": [\"17463250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Loss-of-function of ERBB3 (aberrant splicing leading to truncated protein) causes lethal congenital contractural syndrome type 2 (LCCS2), an autosomal recessive neurogenic arthrogryposis with anterior horn atrophy, establishing that ERBB3 is essential in vivo for generation of Schwann cell precursors that accompany peripheral motor axons.\",\n      \"method\": \"Human genetic mapping, identification of disease-causing ERBB3 splicing mutation in affected families\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human loss-of-function mutation with defined cellular mechanism (Schwann cell precursor generation), replicated across affected families\",\n      \"pmids\": [\"17701904\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ErbB3 and ErbB2 are required for amputation-induced proliferation and migration during zebrafish fin regeneration. NRG1 and PI3K functionally interact with ErbB2/ErbB3 in this process; genetic or chemical inhibition of ErbB signaling reduces progenitor proliferation and migration and expression of transcription factors lef1 and msxB.\",\n      \"method\": \"Zebrafish genetic and chemical modulation of ErbB2/ErbB3, BrdU labeling, cell migration assays, gene expression analysis\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — combined genetic and pharmacological epistasis in an in vivo regeneration model, single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"19133254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Necl-2 (an immunoglobulin-like cell adhesion molecule) interacts in cis with the extracellular region of ErbB3 (but not ErbB2), reducing ligand-induced ErbB2-catalyzed tyrosine phosphorylation of ErbB3. This inhibitory effect is mediated by the protein-tyrosine phosphatase PTPN13, which interacts with the cytoplasmic tail of Necl-2, resulting in inhibition of ErbB3-mediated Rac and Akt activation and suppression of cancer cell movement and survival.\",\n      \"method\": \"Co-immunoprecipitation, domain-specific interaction mapping, siRNA knockdown, Rac/Akt activity assays, cell migration and survival assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP with mechanistic dissection of inhibitory pathway, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"19561085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Despite lacking several key conserved catalytic residues including the catalytic base aspartate, ErbB3 retains sufficient kinase activity to robustly trans-autophosphorylate its intracellular region. The ErbB3 kinase domain binds ATP with Kd ~1.1 µM. Crystal structure of ErbB3 kinase bound to an ATP analogue revealed an inactive-like configuration with a shortened αC-helix. QM/MM simulations defined a phosphoryl transfer reaction pathway that does not require the conserved catalytic base.\",\n      \"method\": \"In vitro kinase assay, ATP binding assay, X-ray crystallography, quantum mechanics/molecular mechanics (QM/MM) simulation, mutagenesis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus in vitro biochemical assays plus mutagenesis plus computational mechanistic modeling, multiple orthogonal Tier 1 methods in one study\",\n      \"pmids\": [\"20351256\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Nrdp1 (RING finger E3 ubiquitin ligase) preferentially associates with the nascent form of ErbB3 at the endoplasmic reticulum (ER), mediating ligand-independent ubiquitination and degradation of ErbB3 via the ER-associated degradation (ERAD) pathway (VCP/p97-dependent). Blocking ER exit does not affect Nrdp1-mediated ubiquitination, and disruption of VCP/p97 accumulates ubiquitinated ErbB3 without degradation.\",\n      \"method\": \"Co-localization at ER, ubiquitination assays, VCP/p97 dominant-negative and siRNA, protein stability assays, fluorescence microscopy\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — defined ER co-localization, ERAD pathway requirement established by multiple mechanistic perturbations, rigorous controls\",\n      \"pmids\": [\"21576364\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Inhibition of PI3K (with XL147) in HER2-overexpressing breast cancer cells causes feedback upregulation of HER3 expression and phosphorylation via FoxO1/FoxO3a transcription factors. Knockdown of FoxO1/FoxO3a suppressed HER3 induction; co-targeting HER3 with siRNA or HER2 inhibitors enhanced PI3K inhibitor efficacy, establishing a feedback loop limiting PI3K inhibitor effectiveness.\",\n      \"method\": \"siRNA knockdown, PI3K inhibitor treatment, Western blotting for pathway activation, co-treatment experiments, xenograft models\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic (siRNA) and pharmacological dissection of feedback loop, in vitro and in vivo validation, multiple orthogonal approaches\",\n      \"pmids\": [\"21368164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ErbB3 loss in luminal mammary epithelium of mice impairs Akt and MAPK signaling, reduces luminal cell proliferation and survival, and shifts gene expression toward a basal/stem cell signature. ErbB3 depletion-induced effects were rescued by activation of Akt and MAPK. Interestingly, luminal ErbB3 loss induced IL-6 and other cytokines that increased growth of basal epithelial cells in a paracrine fashion.\",\n      \"method\": \"Conditional knockout mice, gene expression profiling, siRNA, Akt/MAPK pathway activation rescue experiments, cytokine analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional knockout with epistatic rescue experiments and multiple cellular readouts, in vivo model\",\n      \"pmids\": [\"22178756\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Following heregulin stimulation, erbB3 immunoprecipitates show markedly upregulated kinase activity. Intact activated erbB3 can phosphorylate tyrosine sites in an exogenous peptide substrate, and this activity is abolished by mutagenesis of lysine 723 in the catalytic domain. Enhanced erbB3 kinase activity is dependent on heterointeractions with catalytically active erbB2 (blocked by lapatinib or pertuzumab). Single-particle tracking showed erbB3 homo- and heterodimerization events in real time on live cells.\",\n      \"method\": \"Kinase activity assay from immunoprecipitates, K723 mutagenesis, lapatinib/pertuzumab inhibition, single-particle quantum dot tracking on live cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay with mutagenesis of catalytic residue plus live-cell single-molecule imaging, multiple Tier 1 methods\",\n      \"pmids\": [\"24379439\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ERBB3 somatic mutations (~11% in colon and gastric cancers) transform colonic and breast epithelial cells in a ligand-independent manner, but oncogenic ERBB3 mutant activity is dependent on kinase-active ERBB2. Anti-ERBB antibodies and small molecule inhibitors block mutant ERBB3-mediated oncogenic signaling in vivo.\",\n      \"method\": \"Sequencing of primary tumors, cellular transformation assay, ERBB2 knockdown/inhibition epistasis, in vivo xenograft models\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional characterization of oncogenic mutations with epistasis (ERBB2 dependency), transformation assay, in vivo validation\",\n      \"pmids\": [\"23680147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NEDD4 (E3 ubiquitin ligase) negatively regulates HER3 levels and signaling: NEDD4 WW domains interact with the C-terminal tail of HER3 in a neuregulin-1-independent manner. NEDD4 shRNA knockdown elevated HER3 levels and increased HER3 signaling and cancer cell proliferation in vitro and in vivo.\",\n      \"method\": \"Co-immunoprecipitation, domain mapping, shRNA knockdown, proliferation assays, xenograft models, prostate cancer tissue analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP with domain mapping, gain-of-function (KD of ligase elevates substrate), in vitro and in vivo validation\",\n      \"pmids\": [\"24662824\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TX1-85-1, a covalent ligand, forms a bond with Cys721 in the ATP-binding site of HER3 and inhibits HER3 signaling. Derivatization with hydrophobic adamantane (TX2-121-1) enhances inhibition, causes partial HER3 degradation, and interferes with productive heterodimerization of HER3 with HER2 or c-Met, demonstrating that covalent modification of HER3's pseudokinase ATP site is pharmacologically tractable.\",\n      \"method\": \"Covalent ligand synthesis, mass spectrometry confirmation of covalent modification, cell signaling Western blots, co-immunoprecipitation of HER3 heterodimers\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — covalent modification confirmed by MS with functional signaling and dimerization readouts; first demonstration of HER3 ATP-site druggability\",\n      \"pmids\": [\"25326665\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"EGF and NRG induce HER3 phosphorylation via distinct oligomeric mechanisms depending on co-receptor context. NRG-induced HER3 phosphorylation by EGFR requires asymmetric kinase dimerization without higher-order oligomers; EGF-induced HER3 phosphorylation occurs via a noncanonical mechanism within large receptor clusters; NRG-induced HER3 phosphorylation by HER2 requires cluster formation and asymmetric kinase dimerization.\",\n      \"method\": \"STORM super-resolution microscopy with pair-correlation analysis, receptor phosphorylation assays, ligand-specific stimulation conditions\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — super-resolution microscopy combined with phosphorylation assays defining distinct mechanisms for each ligand/co-receptor context, multiple orthogonal approaches\",\n      \"pmids\": [\"28320942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ROR1 phosphorylates HER3 at Tyr1307 (a previously unidentified site) following neuregulin stimulation, independently of other ErbB family members. Phospho-HER3 Tyr1307 recruits the LLGL2-MAYA-NSUN6 RNA-protein complex, which methylates MST1 (Hippo kinase) at Lys59, leading to MST1 inactivation and YAP target gene activation, osteoclast differentiation, and bone metastasis.\",\n      \"method\": \"Co-immunoprecipitation, phosphospecific antibodies, mutagenesis, RNA-protein complex isolation, methylation assay, in vivo bone metastasis models\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — novel phosphorylation site identified with functional downstream cascade dissected through multiple Co-IPs, mutagenesis, and in vivo validation\",\n      \"pmids\": [\"28114269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Lapatinib (ATP-competitive HER2 inhibitor) stabilizes a specific HER2 conformer that drives HER2-HER3 kinase domain heterocomplex formation in a head-to-head orientation distinct from the canonical asymmetric active dimer. This atypical dimer, combined with HER3 ligand NRG, cooperatively promotes proliferation, providing a mechanistic basis for inhibitor-induced paradoxical pro-proliferative signaling.\",\n      \"method\": \"FRET-based conformational assay, Co-IP of kinase domain complexes, structural modeling, proliferation assays with lapatinib + NRG combinations\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — conformational and biochemical evidence for novel dimer interface combined with functional (proliferation) consequence, multiple complementary methods\",\n      \"pmids\": [\"29712619\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In untransformed cells, HER3 is not phosphorylated by MET in response to ligand stimulation but rather by ligand-independent MET activation caused by MET overexpression. MET phosphorylates HER3 via a mechanism not requiring the allosteric site used by canonical co-receptors EGFR/HER2. HER3 preferentially interacts with MET during maturation along the secretory pathway (before MET extracellular domain cleavage), resulting in accumulation of phospho-HER3 in the Golgi.\",\n      \"method\": \"Co-immunoprecipitation at different maturation states, phosphorylation assays with MET overexpression, allosteric site mutagenesis, subcellular fractionation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — mechanistic dissection of a non-canonical phosphorylation mechanism with Golgi localization, mutagenesis of interaction site, multiple orthogonal approaches\",\n      \"pmids\": [\"30390071\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Single-molecule analysis of endogenous HER2-HER3 heterodimers revealed large conformational fluctuations in juxtamembrane and kinase domains. Despite these fluctuations, individual HER2-HER3 heterodimers catalyze tyrosine phosphorylation at an unusually high rate while simultaneously interacting with multiple downstream signaling effectors, explaining the exceptional signaling potency of this heterodimer.\",\n      \"method\": \"Single-molecule immunoprecipitation, single-molecule FRET, single-molecule kinase activity assay with endogenous receptors\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — single-molecule biochemical reconstitution with endogenous receptors, measuring both conformational dynamics and catalytic rate directly\",\n      \"pmids\": [\"32267234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Cryo-EM structure of the NRG1β-bound near full-length HER2-HER3 dimer revealed that the HER3 dimerization arm is unresolved because apo HER2 does not undergo the ligand-induced conformational change needed to form a HER3 dimerization arm-binding pocket. The oncogenic HER2(S310F) mutant compensates via a stabilizing interaction with the HER3 dimerization arm. Trastuzumab binds both complexes but pertuzumab does not bind HER2(S310F)-HER3, and the HER2(S310F)-HER3 complex undergoes conformational change to accommodate trastuzumab.\",\n      \"method\": \"Cryo-electron microscopy of near full-length HER2-HER3 and HER2(S310F)-HER3 complexes, Fab binding studies\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cryo-EM structure with functional validation of antibody binding, multiple structures including mutant and antibody-bound states\",\n      \"pmids\": [\"34759323\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Co-occurring HER3(E928G) kinase domain mutation enhances HER2/HER3 heterodimerization affinity and reduces neratinib binding to HER2. Co-expression of mutant HER2/HER3 enhances HER2/HER3 co-immunoprecipitation and ligand-independent activation of HER2/HER3 and PI3K/AKT, promoting growth, invasiveness, and resistance to HER2-targeted therapies reversible by PI3Kα inhibitors.\",\n      \"method\": \"Computational structural modeling, co-immunoprecipitation, phosphorylation assays, cell proliferation/invasion assays, PI3Kα inhibitor rescue\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — integrated computational and biochemical/cell biological dissection with epistatic rescue, multiple orthogonal methods\",\n      \"pmids\": [\"34171264\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SorLA interacts directly with HER3, forming a trimeric complex with HER2 and HER3 that attenuates lysosomal degradation of the HER2-HER3 dimer in a Rab4-dependent manner. HRG-mediated signaling supports SorLA transcription downstream of MAPK, creating a feed-forward loop. Loss of SorLA compromised heregulin-induced proliferation and sensitized resistant breast cancer cells to neratinib.\",\n      \"method\": \"Co-immunoprecipitation, Rab4 dominant-negative experiments, lysosomal degradation assays, MAPK inhibition, in vivo zebrafish xenograft model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP and mechanistic dissection of receptor stabilization pathway with in vivo validation, single lab\",\n      \"pmids\": [\"33420373\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"MTK1 (MAP3K4/MEKK4) associates with activated HER3 following HRG-beta1 stimulation in an HER2-activation-dependent manner (blocked by lapatinib). MTK1 is required for HER2/HER3-HRG-induced cell migration and extracellular acidification in breast cancer cells; disruption of actin polymerization inhibits HRG-induced MTK1/HER3 association.\",\n      \"method\": \"Co-immunoprecipitation, lapatinib treatment, cytochalasin D treatment, MTK1 knockdown, migration/acidification assays\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP with multiple mechanistic perturbations and defined functional readouts, single lab\",\n      \"pmids\": [\"24036211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Hepatocyte-specific knockout of ERBB3 (alone or combined with EGFR) diminishes CCl4-induced liver fibrosis in mice, with maximal reduction in the ERBB3 and EGFR-ERBB3 double knockout models. This suggests that EGFR-ERBB3 heterodimeric signaling in hepatocytes plays a more important role in fibrogenesis than EGFR homodimeric signaling.\",\n      \"method\": \"Hepatocyte-specific conditional knockout mice (single and double), CCl4-induced fibrosis model, alpha-SMA quantification, immunohistochemistry\",\n      \"journal\": \"American journal of physiology. Gastrointestinal and liver physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional knockout with epistatic double-KO analysis in well-established disease model with quantitative phenotypic readouts\",\n      \"pmids\": [\"27586651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Alternative splicing of the c-erbB3 gene produces a 1.4-kb transcript encoding a secreted ErbB3 receptor isoform (erbB3-S), in addition to the full-length transmembrane receptor encoded by the 6.2-kb transcript.\",\n      \"method\": \"Northern blot, RACE cloning, cDNA sequencing, genomic structure analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct sequencing and genomic structure analysis establishing splice isoform, single lab\",\n      \"pmids\": [\"7685162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ErbB3 is upregulated in pulmonary artery endothelial cells in pulmonary hypertension. Endothelial cell-specific ErbB3 knockout reduces hypoxia-induced endothelial proliferation, pulmonary artery remodeling, and right ventricular hypertrophy in rodent PH models, while ErbB3 overexpression exacerbates PH. Co-immunoprecipitation and proteomic analysis identified YB-1 as a downstream target; ErbB3 induces nuclear translocation of YB-1, promoting HIF-1/2α transcription. A positive ErbB3-periostin-HIF-1/2α loop was identified.\",\n      \"method\": \"Endothelial cell-specific conditional knockout, AAV-mediated overexpression, co-immunoprecipitation, proteomics, nuclear translocation assays, rodent PH models\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific conditional KO plus overexpression with mechanistic downstream target identification by Co-IP/proteomics, in vivo validation\",\n      \"pmids\": [\"38214194\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ERBB3/HER3 is a receptor tyrosine kinase that binds neuregulin/heregulin ligands via its extracellular domain and signals exclusively through heterodimerization with kinase-active partners (primarily HER2/ERBB2, also EGFR and HER4): although its kinase domain has minimal but non-zero catalytic activity (capable of ATP binding with Kd ~1 µM and trans-autophosphorylation via a non-canonical mechanism lacking the conserved catalytic base), productive phosphorylation of HER3's six YXXM motifs requires transphosphorylation by partner kinases, which then enables direct high-affinity recruitment of the PI3K p85 subunit and potent PI3K/AKT pathway activation; receptor levels are regulated by NEDD4 and Nrdp1 E3 ubiquitin ligases at the endoplasmic reticulum (ERAD pathway), with MET overexpression additionally phosphorylating HER3 in the Golgi during receptor maturation; HER3 is essential in vivo for Schwann cell migration and myelination, mammary epithelial homeostasis, and liver fibrogenesis, and its dysregulation — through overexpression, oncogenic somatic mutations, or feedback upregulation — drives resistance to EGFR/HER2-targeted therapies primarily via sustained PI3K/AKT signaling.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ERBB3/HER3 is a neuregulin/heregulin receptor that operates as a signal-amplifying heterodimerization partner rather than an autonomous kinase, coupling ligand binding to potent PI3K/AKT activation across development, tissue homeostasis, and cancer [#0, #4]. Its extracellular domain binds heregulin with high affinity, triggering tyrosine phosphorylation of HER3 and receptor hetero-oligomerization [#0, #1]. Although its kinase domain lacks several conserved catalytic residues including the catalytic base aspartate, it binds ATP (Kd ~1.1 µM) and supports trans-autophosphorylation through a non-canonical phosphoryl transfer pathway, adopting an inactive-like configuration [#13]; productive phosphorylation, however, depends on catalytically active partner kinases — heregulin-stimulated HER3 kinase activity and signaling require heterointeraction with ERBB2 and are abolished by lapatinib or pertuzumab [#17]. Phosphorylated HER3 presents YXXM motifs that directly recruit the PI3K p85 subunit, with a single motif sufficient and multiple motifs strengthening the interaction, providing the molecular basis for its exceptional PI3K coupling [#4]. The HER2-HER3 heterodimer is an unusually potent signaling unit that catalyzes tyrosine phosphorylation at high rates while engaging multiple effectors simultaneously [#25, #26]. Receptor abundance is restrained by the E3 ubiquitin ligases Nrdp1, which targets nascent HER3 for ERAD at the ER, and NEDD4, which binds the HER3 C-terminal tail [#14, #19]. In vivo, ERBB3 is required for Schwann cell precursor generation, migration, and myelination, and human loss-of-function splicing mutations cause lethal congenital contractural syndrome type 2 (LCCS2) [#6, #10]; it also drives mammary luminal epithelial homeostasis and hepatocyte fibrogenesis [#16, #30]. HER3 dysregulation — via overexpression, oncogenic somatic mutations dependent on kinase-active ERBB2, MET-driven phosphorylation, or FoxO-mediated feedback upregulation after PI3K inhibition — sustains PI3K/AKT signaling and underlies resistance to EGFR/HER2-targeted therapy [#9, #15, #18, #27], and its ATP-binding site is covalently druggable despite minimal catalytic function [#20].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Establishing that ErbB3 is a direct heregulin/NDF receptor answered what ligand engages this orphan ErbB member and showed ligand binding couples to tyrosine phosphorylation of both ErbB3 and a partner receptor.\",\n      \"evidence\": \"Radioligand binding, chemical cross-linking, and phosphorylation assays in transfected cells and breast carcinoma lines\",\n      \"pmids\": [\"8188716\", \"8045292\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish whether ErbB3 signals autonomously or requires a heterodimeric partner\", \"Identity of the >400 kDa hetero-oligomer partner not molecularly defined at this stage\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Synaptic localization of ErbB3 at neuromuscular junctions independent of innervation pointed to a tissue role beyond mitogenic signaling.\",\n      \"evidence\": \"Immunohistochemistry with denervation controls in rodent skeletal muscle\",\n      \"pmids\": [\"8846777\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No causal functional consequence demonstrated\", \"Downstream signaling at synapse not addressed\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Mapping the YXXM motifs as the p85/PI3K docking sites defined the molecular basis for HER3's strong coupling to PI3K/AKT.\",\n      \"evidence\": \"Yeast two-hybrid with chimeric receptor, deletion and Tyr→Phe mutants, in vitro binding\",\n      \"pmids\": [\"9677338\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Used a chimeric receptor with EGFR kinase domain, leaving native phosphorylation source unaddressed\", \"Stoichiometry and signaling output of multi-motif binding not quantified\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Constitutive ErbB3 phosphorylation/PI3K binding driving dedifferentiated phenotypes linked HER3 signaling to malignant cell-state change.\",\n      \"evidence\": \"Mass spectrometry identification and constitutively active ErbB2/ErbB3 chimera in gastric carcinoma cells\",\n      \"pmids\": [\"12618754\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Chimeric construct not equivalent to endogenous receptor regulation\", \"Causality between PI3K and dedifferentiation not isolated\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"In vivo genetics established ERBB3 as essential for Schwann cell proliferation, migration, and myelination, defining its developmental role.\",\n      \"evidence\": \"Zebrafish forward genetics, BrdU, time-lapse imaging, stage-specific ErbB inhibition\",\n      \"pmids\": [\"15797019\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not separate ErbB3-intrinsic versus ErbB2-dependent contributions to each phenotype\", \"Downstream effector pathway in Schwann cells not defined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Reciprocal manipulation showed ErbB3/ErbB2 signaling drives breast tumor intravasation and metastasis without affecting primary growth, separating its invasive role from proliferation.\",\n      \"evidence\": \"Orthotopic models with overexpression and siRNA, chemotaxis/invasion and intravasation assays\",\n      \"pmids\": [\"16452197\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Effector pathway linking HER3 to invasion not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Nuclear ErbB3 enriched in hormone-refractory prostate cancer raised a non-canonical subcellular role correlated with disease progression.\",\n      \"evidence\": \"IHC of 143 samples and subcellular fractionation Western blotting\",\n      \"pmids\": [\"16675564\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of nuclear translocation unknown\", \"Functional role of nuclear HER3 not established\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"MET amplification activating ERBB3-dependent PI3K signaling answered how cancers bypass EGFR inhibition, expanding HER3's partner repertoire beyond ErbB receptors.\",\n      \"evidence\": \"MET-amplified resistant lung cancer lines, combinatorial kinase inhibition, patient specimen analysis\",\n      \"pmids\": [\"17463250\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct versus indirect MET-HER3 phosphorylation not resolved at this stage\", \"Subcellular site of MET-HER3 interaction undefined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"A human loss-of-function ERBB3 splicing mutation causing LCCS2 confirmed in vivo essentiality for Schwann cell precursor generation and motor axon accompaniment.\",\n      \"evidence\": \"Genetic mapping and disease-causing mutation identification in affected families\",\n      \"pmids\": [\"17701904\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular mechanism of precursor failure not dissected biochemically\", \"No genotype-phenotype correlation beyond truncating allele\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Necl-2/PTPN13-mediated cis inhibition of ErbB2-catalyzed ErbB3 phosphorylation identified a negative regulatory axis controlling HER3 output.\",\n      \"evidence\": \"Co-IP, domain mapping, siRNA, Rac/Akt activity and migration/survival assays\",\n      \"pmids\": [\"19561085\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological contexts where Necl-2 regulates HER3 not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Structural and biochemical analysis showed the HER3 'pseudokinase' binds ATP and trans-autophosphorylates via a base-independent mechanism, redefining it as a weakly active rather than dead kinase.\",\n      \"evidence\": \"In vitro kinase and ATP-binding assays, X-ray crystallography, QM/MM simulation, mutagenesis\",\n      \"pmids\": [\"20351256\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological significance of low intrinsic activity versus partner-driven phosphorylation unresolved\", \"In vivo contribution of autophosphorylation not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Nrdp1 and FoxO-driven feedback findings defined opposing controls on HER3 abundance — ERAD degradation of nascent receptor and transcriptional induction upon PI3K inhibition that limits drug efficacy.\",\n      \"evidence\": \"ER co-localization and ubiquitination/VCP perturbation assays; PI3K inhibitor treatment with FoxO1/3a knockdown and xenografts\",\n      \"pmids\": [\"21576364\", \"21368164\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interplay between ERAD turnover and feedback transcription not integrated\", \"Trigger selecting nascent versus mature HER3 for Nrdp1 incompletely defined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Conditional knockout showed luminal mammary ErbB3 sustains Akt/MAPK-dependent proliferation and survival and represses a basal/stem program, with paracrine cytokine consequences.\",\n      \"evidence\": \"Conditional knockout mice, expression profiling, Akt/MAPK rescue, cytokine analysis\",\n      \"pmids\": [\"22178756\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets of HER3 signaling in luminal cells not mapped\", \"Paracrine IL-6 source and receptor circuit only partially defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Heregulin-induced HER3 kinase activity dependent on K723 and on catalytically active ERBB2, plus live-cell dimerization imaging, reconciled intrinsic activity with obligate partner dependence.\",\n      \"evidence\": \"Kinase assay from immunoprecipitates, K723 mutagenesis, lapatinib/pertuzumab inhibition, single-particle tracking\",\n      \"pmids\": [\"24379439\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of HER3 versus HER2 catalysis to substrate phosphorylation not quantified\", \"Substrate repertoire of activated HER3 not broadly defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Oncogenic ERBB3 somatic mutations transforming epithelial cells in a ligand-independent but ERBB2-dependent manner established HER3 as a cancer driver and therapeutic target.\",\n      \"evidence\": \"Tumor sequencing, transformation assays, ERBB2 epistasis, xenografts, antibody/inhibitor blockade\",\n      \"pmids\": [\"23680147\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural mechanism by which mutations activate signaling not resolved here\", \"Tissue-specificity of mutation effects not addressed\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"MTK1 association with HER3 in an actin- and ERBB2-activation-dependent manner identified a migration effector downstream of HER2/HER3.\",\n      \"evidence\": \"Co-IP, lapatinib and cytochalasin D treatment, MTK1 knockdown, migration/acidification assays\",\n      \"pmids\": [\"24036211\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct versus indirect MTK1-HER3 binding not resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"NEDD4 binding the HER3 C-terminal tail and a covalent ATP-site ligand together established a second degradative regulator and the surprising druggability of the HER3 pseudokinase pocket.\",\n      \"evidence\": \"Co-IP/domain mapping with shRNA and xenografts; covalent ligand synthesis with MS confirmation and dimerization assays\",\n      \"pmids\": [\"24662824\", \"25326665\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"NEDD4 versus Nrdp1 division of labor in HER3 turnover not delineated\", \"Cellular potency and selectivity of covalent ATP-site ligands not fully characterized\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Super-resolution and novel-site studies revealed ligand/co-receptor-specific oligomeric mechanisms of HER3 phosphorylation and a ROR1-driven Tyr1307 branch coupling HER3 to a methylation cascade and bone metastasis.\",\n      \"evidence\": \"STORM with pair-correlation; ROR1 Co-IP, phosphospecific antibodies, methylation assays, in vivo metastasis models\",\n      \"pmids\": [\"28320942\", \"28114269\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of ROR1-Tyr1307 axis across tissues unknown\", \"How oligomeric state selects downstream effector outputs not resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Single-molecule and mechanistic work showed HER2-HER3 dimers catalyze phosphorylation at high rates despite conformational flexibility, and that MET phosphorylates HER3 ligand-independently in the Golgi via a non-allosteric mechanism.\",\n      \"evidence\": \"Single-molecule IP/FRET/kinase assays with endogenous receptors; MET overexpression, allosteric-site mutagenesis, fractionation\",\n      \"pmids\": [\"32267234\", \"30390071\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of Golgi-localized phospho-HER3 not established\", \"How the secretory-pathway HER3-MET interaction influences surface signaling unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Cryo-EM, mutation, and trafficking studies defined the structural basis of HER2-HER3 dimerization, how oncogenic mutations (HER2 S310F, HER3 E928G) reshape the dimer and drug binding, and how SorLA stabilizes the dimer against lysosomal degradation.\",\n      \"evidence\": \"Cryo-EM with Fab binding; structural modeling, Co-IP, proliferation/invasion and PI3Kα rescue; SorLA Co-IP, Rab4 perturbation, zebrafish xenografts\",\n      \"pmids\": [\"34759323\", \"34171264\", \"33420373\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of the HER3 kinase-active or fully signaling-competent dimer not captured\", \"SorLA findings are single-lab and lack reciprocal structural validation\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Endothelial ERBB3 was shown to drive pulmonary hypertension through a YB-1/HIF and periostin feed-forward loop, extending HER3 biology to vascular remodeling.\",\n      \"evidence\": \"Endothelial-specific knockout and AAV overexpression in rodent PH, Co-IP/proteomics, nuclear translocation assays\",\n      \"pmids\": [\"38214194\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the YB-1 axis requires canonical HER3 PI3K signaling not dissected\", \"Ligand/partner driving endothelial HER3 activation in PH undefined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How HER3's distinct activation routes (partner ErbB kinases, MET, ROR1) and degradation controls (Nrdp1, NEDD4) are integrated to set context-specific signaling output and effector selection remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking oligomeric state, phospho-site usage, and downstream effector choice\", \"Functional role of nuclear and secreted HER3 isoforms not established\", \"In vivo contribution of intrinsic HER3 catalysis versus partner phosphorylation untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [13, 17]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [13]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 2, 17]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [14]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [24]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 9, 17]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [10, 18, 27]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [6, 10, 11]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [14, 19]}\n    ],\n    \"complexes\": [\n      \"HER2-HER3 heterodimer\",\n      \"HER3-PI3K (p85) complex\"\n    ],\n    \"partners\": [\n      \"ERBB2\",\n      \"EGFR\",\n      \"PIK3R1\",\n      \"MET\",\n      \"NEDD4\",\n      \"ROR1\",\n      \"SORL1\",\n      \"MAP3K4\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}